Nutravigilance: Principles and practices to enhance adverse event reporting in the dietary supplement and natural products industry

International Journal of Food Sciences and Nutrition

Volumn 65, Issue 2, 2014, Pages 129-134

  Schmitz, Stephen M ^a   Lopez, Hector L ^a,b   Mackay, Douglas ^c  

^a Supplement Safety Solutions   (United States)

^b The Center for Applied Health Sciences   (United States)

^c International and Scientific Affairs   (United States)

Author keywords

Adverse event; Dietary supplement; DSHEA; FDA regulation of dietary supplements; Nutravigilance; Pharmacovigilance; Serious adverse event; Supplement safety

Indexed keywords

BIOLOGICAL PRODUCT;

ADVERSE DRUG REACTION; DIET SUPPLEMENTATION; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; PRODUCT SAFETY; REVIEW; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BIOLOGICAL PRODUCTS; CONSUMER PRODUCT SAFETY; DIETARY SUPPLEMENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84894538479     PISSN: 09637486     EISSN: 14653478     Source Type: Journal    
DOI: 10.3109/09637486.2013.836743     Document Type: Review

References (36)

1. Artz MB, Harnack LJ, Duval SJ, Arnett DK, Luepker RV. 2006. Use of nonprescription medication for perceived cardiovascular health. Am J Prev Med 30:78-81
2. Barnes PM, Powell-Griner E, McFann K, Nahin RL. 2002. Complementary and alternative medicine use among adults: United States. Adv Data 343:1-19
3. Cardellina JH 2nd. 2002. Challenges and opportunities confronting the botanical dietary supplement industry. J Nat Prod 65:1073-1084
4. CIOMS 2010 Practical aspects of signal detection in pharmacovigilance. Report of CIOMS working group VIII. Geneva, ISBN 92 9036 082
5. Cohen PA. 2012a. Assessing supplement safety-The FDAs controversial proposal. NEJM 366:389-391
6. Cohen PA. 2012b. A false sense of security? The US Food and Drug Administrations framework for evaluating new supplement ingredients. Antioxid Redox Signal 16:458-460
7. Cohen PA, Ernst E. 2010. Safety of herbal supplements: A guiDe for cardiologists. Cardiovasc Therapeut 28:246-253
8. Dietary Supplement Health and Education Act. 1994. Washington, DC: Center for Food Safety and Applied Nutrition. Available at: Http:// www.fda.gov/opacom/laws/dshea.html#sec3
9. Eudravigilance. 2013. Available at: Http://eudravigilance.ema.europa.eu/ human/ichAndEtransmission03.asp. Accessed on 29 April 2013
10. Fabricant D. 2013. Safety of dietary supplements. Comments by Daniel Fabricant, PhD, February 8, 2013, Presentation, sliDe 23. Available at: Http://www.nynjforwarders-brokers.org/clientuploads/Safety%20of %20Dietay%20Supplements%20(2).pps. Accessed on 23 April 2013
11. FD&C Act. 1938. Pub. L. No. 75-717, 52 Stat. 1040 (source cited on FDA.gov
12. FD&C Act 2006. Part H, Section 761, 379aa-1. p 377-379
13. Federal Register, (Sep 15, 2008). Based on a 2000 FDA-Commissioned Study; GAO-09-250, 16
14. GAO-09-150. 2009. Report to Congressional Requesters: Dietary Supplements: FDA should take further actions to improve oversight and consumer understanding. GAO-09-250; January 2009
15. GAO-13-244. 2013. Dietary supplements. FDA may have opportunities to expand its use of reported health problems to oversee products. March 2013
16. Gardiner P, Graham RE, Legedza AT, Eisenberg DM, Phillips RS. 2006. Factors associated with dietary supplement use among prescription medication users. Arch Intern Med 166:1968-1974
17. Gardiner P, Sarma DN, Dog TL, Barrett ML, Chavez ML, Ko R, Mahady GB, et al. 2008. The state of dietary supplement adverse event reporting in the United States. Pharmacoepidemiol Drug Safety 17: 962-970
18. Gilmour J, Harrison C, Asadi L, Cohen MH, Vohra S. 2011. Natural health product-drug interactions: Evolving responsibilities to take complementary and alternative medicine into account. Pediatrics 128:S155-S160
19. Good Pharmacovigilance Practice Guide. 2009. Compiled by the medicines and healthcare products regulatory agency. London Pharmaceutical Press
20. Grebow J. 2011. How many dietary supplement GMPs inspections has FDA performed so far? Nutritional Outlook. Available at: Http:// www.nutritionaloutlook.com/article/how-many-dietary-supplementgmp-inspections- has-fda-performed-so-far. Published May 24, 2011. Accessed on 2 January 2013
21. Guideline on good pharmacovigilance practices (GVP), 2012. Module I; EMA/541760/2011
22. Hazell L, Shakir SAW. 2006. Under-reporting of adverse drug reactions: A systematic review. Drug Safety 9:385-396
23. Health Data Management. 2012. Available at: Http://www.healthdata management.com/news/hhspatient-harm-events-safety-hospitals. Accessed on 02 January 2013
24. Jiang T. 2009. Re-Thinking the dietary supplement laws and regulations 14 years after the Dietary Supplement Health and Education Act implementation. Int J Food Sci Nutr 60:293-301
25. Mehta B. 2012. FDA inspection trends for supplement manufacturers: Product testing, record keeping, standard operating procedures and specifications remain key to compliance. Nutraceuticals World. Available at: Http://www.nutraceuticalsworld.com/contents/view-online-exclusives/2012-12-06/ fda-inspection-Trends-for-supplementmanufacturers. Published December 6, 2012. Accessed on 2 January 2013
26. Millen AE, Dodd KW, Subar AF. 2004. Use of vitamin, mineral, nonvitamin, and nonmineral supplements in the United States: The 1987, 1992, and 2000 National Health Interview Survey results. J Am Diet Assoc 104:942-950
27. Nutrition Business Journal. 2012. NBJs Supplement Business Report 2012. Boulder, CO: Penton Media Inc. Available at: Http:// newhope360.com/research/ supplement-business-report. Accessed on 12 December 2012
28. Office of Inspector General (OIG). 2001. Report adverse event reporting for dietary supplements: An inadequate safety valve. Washington, DC
29. Rogers EA, Gough JE, Brewer KL 2001. Are emergency department patients at risk for herb-drug interactions? Acad Emerg Med 8:932-934
30. Scott GN, Elmer GW. 2002. Update on natural product-drug interactions. Am J Health-Syst Pharm 59:339-347
31. Shekelle PG, Hardy ML, Morton SC, Maglione M, Jojica WA, Suttorp MJ, Rhodes SL, et al. 2003. Efficacy and safety of ephedra and for weight loss and athletic performance: A meta-Analysis. J Am Med Assoc 289:1537-1545
32. U.S. Food and Drug Administration. 2012. Reporting serious problems to FDA: Reporting by health professionals. U.S. Food and Drug Administration. Available at: Http://www.fda.gov/Safety/ MedWatch/HowToReport/ucm085568.htm Accessed on 10 October 2012. Accessed on 2 January 2013
33. Valli G, Giardina E-GV, Giardina E-GV. 2002. Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular effects. J Am Coll Cardiol 39:1083-1095
34. Walenga JM, Adiguzel C. 2010. Drug and dietary interactions of the new and emerging anticoagulants. Intern J Clin Pract 64:956-967
35. WHO. 2002. The importance of pharmacovigilance safety monitoring of medicinal products. WHO, 2002; ISBN 92 4 159915 7 (NLM classification QV 38
36. Wollschlaeger B. 2003. The dietary and supplement and healTheducation act and supplements: Dietary and nutritional supplements need no more regulation. Int J Toxicol 22:391-392